Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranpirnase with Pemetrexed/Carboplatin in NSCLC
NCT01184287Phase 2Withdrawn
- Sponsor
- Tamir Biotechnology, Inc.
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ranpirnase in non-small cell lung cancer (NSCLC), sponsored by Tamir Biotechnology, Inc.. Status: withdrawn.
02
Drugs
ranpirnase
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01184287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01184287.